Clostridioides difficile (pathogenic suppression is a therapeutic objective, not a molecule) (C. difficile (when referring to the organism; no standard abbreviation for the "suppression" target))

Clostridioides difficile is a Gram-positive, spore-forming anaerobic bacterium that is a leading cause of healthcare-associated infectious diarrhea. Pathogenicity stems from toxins (TcdA, TcdB, and binary CDT) encoded in the pathogenicity locus (PaLoc) or CdtLoc, causing severe intestinal inflammation and tissue damage. Suppressing pathogenic C. difficile involves killing or inhibiting the bacterium, neutralizing its toxins, restoring colonization resistance by healthy microbiota, and preventing spore formation and recurrence. Major challenges include antibiotic resistance, high recurrence rates, and the rise of hypervirulent strains with mutations conferring drug or antibody escape. Therapeutic strategies encompass antibiotics, toxin-neutralizing antibodies (e.g., bezlotoxumab), microbiota restoration (e.g., FMT), and novel agents like bacteriophages and spore germination inhibitors. In summary, "Pathogenic Clostridioides difficile suppression" is not a molecular target but rather an umbrella therapeutic goal addressing a major pathogen through multiple mechanisms and molecular targets. For future drug targeting, specific molecules within the organism (e.g., TcdB, Spo0A) or pathogenic processes are canonical drug targets.

Other names

Clostridium difficile (former name)C. difficile (common abbreviation)CDI (Clostridioides difficile infection)

Direct bacterial killing/inhibition (antibiotics) Restoration of healthy microbiota to outcompete pathogen Inhibition or neutralization of C. difficile toxins with antibodies Disruption of spore formation and germination (targeting sporulation factors or germination pathways) Bacteriophage-mediated lysis Prevention of dysbiosis to reduce susceptibility to infection